{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-122272","form_type":"8-K","ticker":"SGMT","cik":"0001400118","company_name":"Sagimet Biosciences Inc.","filed_at":"2025-12-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.308931+00:00","generated_at":"2026-05-16T12:43:16.144697+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Sagimet announces positive Phase 1 PK data for denifanstat/resmetirom combo in MASH","bullets":["Phase 1 PK trial (NCT07216313) of denifanstat + resmetirom in 40 healthy adults met objectives; combination well-tolerated, no SAEs.","PK data support further development; no drug-drug interaction signals observed; no treatment discontinuations.","Company plans Phase 2 proof-of-concept trial in MASH F4 fibrosis patients in 2H 2026 pending regulatory consultation.","Global license agreement with TAPI (TEVA affiliate) to develop once-daily fixed-dose combination tablet for Phase 3."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-122272","json":"https://secwatch.observer/filing/0001104659-25-122272.json","markdown":"https://secwatch.observer/filing/0001104659-25-122272.md","text":"https://secwatch.observer/filing/0001104659-25-122272.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1400118/000110465925122272/0001104659-25-122272-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1400118/000110465925122272/tm2533462d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T12:43:16.144697+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}